SCYX Stock Analysis: Buy, Sell, or Hold?
SCYX - SCYNEXIS, Inc.
$5.26
0.16 (3.14%)
â˛
5d:
+3.34%
30d:
+41.02%
90d:
+619.27%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 12, 2026
0d
Get Alerted When SCYX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: SCYX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: SCYX is fairly priced but lacks strong directional signals. At 0% expected growth, valuation appears cheap. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: SCYX is currently trading at $5.26, which is considered slightly high relative to its 30-day fair value range of $4.02 to $5.26. From a valuation perspective, the stock is trading at a discount (Forward PE: -2.3) compared to its historical average (1.5). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, SCYX is in a strong uptrend. Immediate support is located at $4.65, while resistance sits at $5.52. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: SCYX scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.55 (+594.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SCYX is in a strong uptrend. Immediate support is located at $4.65, while resistance sits at $5.52. The stock is showing strong short-term momentum, up 3.1% recently.
Market Sentiment: SCYX scores 24/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $36.55 (+594.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$4.02 -
$5.26
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.5%
All Signals
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (24/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.1%)
- BULLISH: Trading 594.8% below Wall St target ($36.55)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 46/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$4.02 -
$5.26
Current vs Trading Range
SLIGHTLY HIGH
Expected Move (7 Days)
Âą$0.72
(13.7%)
Support & Resistance Levels
Support Level
$4.65
Resistance Level
$5.52
Current Trend
Strong Uptrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.27
Wall Street Target
$36.55
(+594.8%)
Revenue Growth (YoY)
-82.8%
Profit Margin
-53.3%
PE vs Historical
-2.3 vs 1.5
CHEAP
Share & Embed Analysis
Last updated: August 24, 2026 9:23 PM ET
Data refreshes hourly during market hours. Next update: 10:23 PM
Data refreshes hourly during market hours. Next update: 10:23 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCYX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences IâĻ |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$101 | 50 HOLD |
|
UTHR
United Therapeutics CorpâĻ |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst PharmaceuticalsâĻ |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
